ABSTRACT
Introduction
Sirtuins, NAD-dependent protein deacetylases, require NAD+ for enzymatic activity. Recent research has indicated that sirtuins have a key role in the regulation of gene expression, the cell cycle, apoptosis, neurodegeneration and several age-related diseases. In mammals, there are seven sirtuin isoforms (SIRT-1-7) that catalyze specific lysine substrate deacetylation.
Areas Covered
This review explains the current information on the structure, function and importance of sirtuin modulators. It also explores the possible therapeutic applications of sirtuin modulators and related small molecules in the context of various diseases.
Expert opinion
Sirtuin’s modulators open a new area of research for targeting pathological conditions. Sirtuin modulators, through their targeted function, may provide a possible tool for the amelioration of various diseases. However, the search of activators/inhibitors for sirtuins needs further research. The structural elucidation of sirtuins will create an understanding for the development of isoform-specific selective modulators. This could be a useful tool to determine the functions of individual sirtuins as potential therapeutic agents.
Article highlights
Sirtuins, classified as NAD+-dependent histone deacetylases, regulate several metabolic pathways, gene expression, cell cycle, and apoptosis in both prokaryotes and eukaryotes.
Mammals express seven sirtuin isoforms (SIRT-1–7) which differ in their subcellular localization and substrate specificities.
Sirtuins provide possible targets to treat various diseases such as neurological diseases, cardiovascular diseases, and cancer.
Small-molecule sirtuin activators/inhibitors have proven to be effective therapeutic interventions.
Sirtuin activators or inhibitors might provide an important insight into the pathophysiology of various diseases.
This box summarizes key points contained in the article.
Declaration of interest
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.